share_log

Piper Sandler Maintains Humacyte(HUMA.US) With Hold Rating, Maintains Target Price $6

Futu News ·  Nov 14 04:31  · Ratings

Piper Sandler analyst Allison Bratzel maintains $Humacyte (HUMA.US)$ with a hold rating, and maintains the target price at $6.

According to TipRanks data, the analyst has a success rate of 72.3% and a total average return of 28.0% over the past year.

AnalystRecentRatingAutoNews_81024558263479_20241114_fa3a59c0d92b8a16ce10a5c6b9b2b6a5864a0988_1731591066594531_nn_en

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment